Chungmo Yang

Chungmo Yang

Auto-generated profile, based on publicly available information

Chungmo Yang

Institute for Molecular Science and Fusion Technology, Kangwon National University, Chuncheon 24341, Republic of Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2024 in Advanced Materials
Verified
Journal Article
Closed access
JDJ. Deng
J. Deng
ZZZ. Zhao
Z. Zhao
XYXin Yi Yeo
Xin Yi Yeo
CYC. Yang
C. Yang
JYJ. Yang
J. Yang
Nam-Joon ChoNam-Joon Cho
Nam-Joon Cho

30 August 2024 in Biomaterials
Verified
Journal Article
Closed access
NCNanum Chung
Nanum Chung
CYChungmo Yang
Chungmo Yang
HYHeeseon Yang
Heeseon Yang
JSJungwoo Shin
Jungwoo Shin
CSChae Young Song
Chae Young Song
JLJung Ryeol Lee
Jung Ryeol Lee

7 February 2008
Verified
Conference Paper
Closed access
PDF file
SYSang Kyeong Yun
Sang Kyeong Yun
JSJongHyeong Song
JongHyeong Song
SASeungDo An
SeungDo An
IYInJae Yeo
InJae Yeo
YCYoonJoon Choi
YoonJoon Choi
EBEl-Mostafa Bourim
El-Mostafa Bourim
A diffractive optical modulator has been fabricated based on a micromachining process. Novel properties of its fast response time and dynamics were fully understood and demonstrated for the strong potentials in embedded mobile laser display. Bridged thin film piezo-actuators with so called open mirror diffraction structure has been designed. Optical level package also was achieved to successfully prove its display application qualities. Display circuits and driving logic were developed to finally confirm the single-panel laser display at a 240Hz VGA (640×480). With its efficiency of more than 75% and 13cc volume optical engine with the MEMS-based VGA resolution SOM showed 7 lm brightness at a 1.5W electrical power consumption. Detailed design principle, fabrication, packaging and performances of the invented SOM are described.

1 January 2024 in Biomaterials Research
Verified
Journal Article
Open access
CYChungmo Yang
Chungmo Yang
HYHeeseon Yang
Heeseon Yang
Kangwon LeeKangwon Lee
Kangwon Lee
NCNanum Chung
Nanum Chung
JSJungwoo Shin
Jungwoo Shin
JLJung Ryeol Lee
Jung Ryeol Lee
Hormone replacement therapy (HRT) has been a primary method in menopausal women and patients with ablated ovaries, but safety has been a concern. Cell-based HRT has emerged as an alternative approach without side effects causing pharmaceutical HRT via 3-dimensionally engineered constructs layering ovarian hormone-producing cells. In this study, we applied micro-sized ovarian cell-laden hydrogel beads as an approach to cell-based HRT using a minimally invasive method in the menopausal rat model. Here, we constructed GC/TC-laden microbeads (GTBs; GC, granulosa cell; TC, theca cell) that allow crosstalk between endocrine cells, encapsulating multiple beads for the figuration of the original ovary. We assessed the ovarian hormone production function of GTB through in vitro culture for 90 days. We applied it to a menopausal rat model and confirmed that GTB-injected rats restored their endocrine function, leading to the regeneration of the thinned endometrium and the maintenance of regular estrous cycles in some individuals. Additionally, it was observed to alleviate menopausal symptoms, including body weight gain and osteoporosis. Notably, the GTB-injected rats did not show mammary gland hyperplasia observed in the pharmaceutical HRT groups and exhibited fewer p53- and KI67-positive and an increase in phosphatase and tensin homolog-positive mammary gland epithelial cells compared to pharmaceutical hormone-treated rats. These results suggest that GTB-based HRT could present a lower risk of breast cancer compared to conventional pharmaceutical-HRT use. Our study highlights the potential of cell-based HRT using an injectable artificial ovary, offering a safer alternative for women requiring HRT.

1 October 2025 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
CYChungmo Yang
Chungmo Yang
NCNanum Chung
Nanum Chung
CSChaeyoung Song
Chaeyoung Song
Kangwon LeeKangwon Lee
Kangwon Lee
JSJungwoo Shin
Jungwoo Shin
JLJung Ryeol Lee
Jung Ryeol Lee
The development of artificial ovaries presents a promising strategy for patients facing infertility due to chemotherapy or high metastatic potential cancers, where conventional ovarian tissue transplantation poses significant risks. Our study introduces an “injectable artificial ovary” leveraging a xenogeneic extracellular matrix (ECM) hydrogel derived from bovine ovarian tissue. The ECM hydrogel obtained from bovine ovaries and prepared through decellularization, milling, and digestion is injectable and thermo-responsive, preserving the matrix structure without cytotoxicity. This innovative approach delivers a non-surgical alternative for fertility preservation by harnessing the bioactive and adaptable properties of ECM hydrogels to support ovarian follicle maturation and restore endocrine functions. In our results, the hydrogel demonstrated temperature-responsive gelation and biocompatibility, promoting follicle development and increasing 17β-estradiol secretion. Such advancements highlight the potential of this technique to redefine fertility treatments and regenerative medicine. Notably, the in situ development of ovarian follicles within the injected hydrogel led to successful ovulation after subcutaneous implantation. Although our study did not demonstrate oocyte maturation and fertilization, our findings suggest that this approach could serve as a heterotopic artificial ovary, offering a promising solution for fertility preservation in patients with high metastasis risk cancers who cannot undergo conventional treatments. This strategy advances artificial ovary technologies, presenting new possibilities for reproductive health and fertility preservation interventions.

22 January 2026 in Biomaterials Research
Verified
Journal Article
Open access
CYChungmo Yang
Chungmo Yang
Hyuk Sang YooHyuk Sang Yoo
Hyuk Sang Yoo
Advances in cancer therapy, delayed parenthood, and an increasing number of reproductive disorders have intensified the need for the effective preservation of fertility. However, current clinical strategies such as ovarian tissue cryopreservation, transplantation, and hormonal stimulation remain limited in scope and efficacy. Biomaterials have emerged as powerful tools to overcome these limitations, enabling fertility preservation and functional restoration of reproductive and endocrine systems. Recent progress has included the development of hydrogel-based systems for in vitro follicle maturation, bioengineered scaffolds for ovarian tissue support, and artificial ovaries capable of hormone secretion and oocyte development. These platforms are increasingly incorporating immunomodulatory features to address rejection and enhance graft integration. Beyond preservation, biomaterials are also being harnessed to repair reproductive damage caused by conditions such as primary ovarian insufficiency, intrauterine adhesions, and endometriosis. Through tunable biochemical and mechanical properties, materials can direct tissue regeneration, modulate inflammation, and restore physiological functions. Emerging technologies, including biofabrication with reproductive-specific bioinks, organoid models, hormone-responsive systems, and artificial intelligence-driven biomaterial designs, are accelerating innovation toward translational applications. Collectively, these developments represent a paradigm shift in reproductive medicine from passive preservation to active regenerative strategies. This review highlights the state-of-the-art biomaterial-enabled fertility restoration and outlines future directions toward personalized, functional, and clinically viable solutions.